Business Overview: Abeona Therapeutics Inc. (NASDAQ: ABEO)

---

Executive Summary

Abeona Therapeutics Inc. is a Delaware-incorporated, Cleveland-manufacturing-based commercial-stage biopharmaceutical company focused on cellular and genetic therapies for life-threatening rare diseases. The company achieved a major inflection point on April 28, 2025, when the FDA approved its lead product ZEVASKYN® — described as the first and only autologous cell-based gene therapy for wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin-blistering disease.

Abeona generates modest trailing revenue of roughly $25.5 million against a net loss of about $62.9 million, typical of an early-commercial-stage rare disease biotech. The market has assigned it a roughly $310 million market capitalization, though third-party discounted-cash-flow estimates cited alongside the stock have flagged the shares as potentially overvalued relative to current fundamentals — underscoring that ABEO's value is largely a bet on ZEVASKYN's commercial ramp and pipeline optionality rather than current cash flow.

---

1. Core Business Model & How They Work

Abeona's business model combines three value-creation levers typical of a commercial-stage rare disease gene therapy company:

1. Commercializing ZEVASKYN® — a one-time, autologous (patient's-own-cell-based) gene therapy that inserts a functional COL7A1 gene into a patient's own skin cells via a retroviral vector, manufactured into credit-card-sized sheets and surgically applied to chronic wounds. In its pivotal VIITAL™ trial, ZEVASKYN healed large chronic wounds that had been open for an average of 6.2 years, with no serious treatment-related adverse events — a strong efficacy signal in an indication with essentially no prior effective treatment.
2. Monetizing regulatory incentives — Abeona earned a Priority Review Voucher (PRV) upon ZEVASKYN's approval and sold it in May/June 2025 for gross proceeds of $155.0 million, a meaningful one-time non-dilutive cash infusion common in rare-pediatric-disease drug development.
3. In-house manufacturing — the Elisa Linton Center in Cleveland provides cGMP-compliant retroviral vector production and serum-free, suspension-based bioreactor technology, giving Abeona direct control over ZEVASKYN's complex, autologous manufacturing process — a capability that is difficult and capital-intensive for competitors to replicate.

Abeona also selectively out-licenses earlier-stage programs (Sanfilippo syndrome to Ultragenyx, Rett syndrome to Taysha Gene Therapies) to generate milestone/royalty economics while focusing internal capital on its most differentiated in-house programs.

---

2. Business Segments

Abeona does not report formal financial segments; its business is best understood by program:

• ZEVASKYN® (Commercial) — approved autologous cell-based gene therapy for RDEB wounds, now being rolled out through four activated Qualified Treatment Centers at major U.S. children's hospitals and academic medical centers, with broad national and regional commercial insurer coverage plus Medicare/Medicaid coverage secured.
• AIM™ AAV Ophthalmic Pipeline — proprietary capsid-based in-vivo gene therapies in development: ABO-503 (X-linked retinoschisis, IND anticipated 2026), ABO-504 (Stargardt disease), and ABO-505 (autosomal dominant optic atrophy).
• Out-licensed Programs — Sanfilippo syndrome (Ultragenyx) and Rett syndrome (Taysha Gene Therapies), generating milestone/royalty potential without further internal R&D spend.

---

3. Product Portfolio

• ZEVASKYN® (prademagene zamikeracel) — FDA-approved autologous cell-based gene therapy for RDEB wound healing; Abeona's sole approved, revenue-generating product.
• ABO-503, ABO-504, ABO-505 — pipeline AAV gene therapies for rare inherited eye diseases, built on Abeona's proprietary AIM™ capsid engineering platform.
• Out-licensed Sanfilippo syndrome and Rett syndrome programs — no longer internally funded but retained for milestone/royalty upside.

---

4. Competitive Landscape

Abeona operates in the ultra-rare / orphan gene therapy space, where competition is defined less by direct product rivalry (given how narrow each indication is) and more by platform and manufacturing capability, and by the handful of other companies pursuing adjacent rare disease and gene therapy programs.

Key competitive dynamics:

• RDEB / dermatology gene therapy — ZEVASKYN faces limited direct competition given the rarity of RDEB and its status as the only approved autologous cell-based gene therapy for this indication, though other modalities (e.g., topical/gene-therapy competitors in adjacent epidermolysis bullosa treatments) exist.
• AAV gene therapy / ophthalmology — Abeona's pipeline competes with other gene therapy developers pursuing inherited retinal diseases, an active area of biotech investment given several precedent approvals in the space.
• Manufacturing capability — few competitors have Abeona's combination of in-house cGMP retroviral vector manufacturing and serum-free suspension bioreactor technology, a meaningful differentiator in a field where manufacturing complexity is often the binding constraint on commercial scale-up.

---

5. Strategic Strengths & Risks

Competitive Strengths

• First-and-only approved therapy in its indication — ZEVASKYN's regulatory exclusivity and clinical differentiation (healing wounds open for years, with no serious treatment-related adverse events) give Abeona a genuine, if narrow, first-mover moat in RDEB.
• In-house manufacturing control — the Elisa Linton Center gives Abeona direct control over a technically difficult, capital-intensive manufacturing process, supporting both quality control and margin capture versus outsourcing to a CDMO.
• Non-dilutive capital from the PRV sale ($155.0 million) meaningfully extends Abeona's cash runway without diluting shareholders further, a significant strategic asset for a still-loss-making company.
• Diversified pipeline optionality — the AIM™ AAV ophthalmic programs and out-licensed Sanfilippo/Rett programs provide multiple additional shots on goal beyond ZEVASKYN alone.

Strategic Risks

• Extremely narrow addressable population — RDEB is an ultra-rare disease, meaning ZEVASKYN's total addressable patient population and peak revenue potential are inherently small versus mainstream pharmaceutical products.
• Early, unproven commercial ramp — with only four treatment centers activated and a therapy that requires complex surgical administration, ZEVASKYN's real-world uptake and reimbursement execution remain largely unproven at scale.
• Continued heavy cash burn — a $62.9 million trailing net loss against $25.5 million of revenue means Abeona remains dependent on the PRV proceeds and/or further capital raises to fund both ZEVASKYN's commercial scale-up and pipeline development.
• Valuation risk — external DCF-based fair value estimates well below the current trading price suggest the market may be pricing in more optimistic pipeline/commercial outcomes than current fundamentals support.
• Pipeline concentration and binary trial risk — value beyond ZEVASKYN depends heavily on AAV ophthalmic program success in a competitive gene therapy field, where clinical setbacks are common.

---

6. Financial Overview

The $155 million PRV sale materially strengthens Abeona's balance sheet and cash runway relative to its trailing revenue and losses, but the company's path to sustainable profitability still depends on ZEVASKYN's real-world commercial ramp across a very small eligible patient population.

---

7. Summary Conclusion

Abeona Therapeutics has crossed the critical threshold from clinical-stage to commercial-stage biotech with ZEVASKYN's FDA approval — a genuine first-and-only therapy in a devastating rare disease with clear clinical differentiation and in-house manufacturing control that competitors would find difficult to replicate quickly. However, the ultra-rare nature of RDEB caps ZEVASKYN's revenue ceiling, the commercial rollout is still in its earliest stages, and continued heavy cash burn means Abeona's broader value — including its AAV ophthalmic pipeline — remains largely speculative pending further clinical and commercial execution. The $155 million non-dilutive PRV sale meaningfully de-risks near-term financing needs, but Abeona's durability as an investment case depends on successfully scaling a complex, surgically-administered cell therapy in a very small patient population while its pipeline programs mature.